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Abstract
AIM
To evaluate novel risk factors and biomarkers of car­
diovascular disease in celiac disease (CD) patients 
compared with healthy controls. 
METHODS
Twenty adult patients with recent diagnosis of CD and 
20 sex, age and body mass index­matched healthy 
controls were recruited during a period of 12 mo. 
Indicators of carbohydrate metabolism, hematological 
parameters and high sensitive C reactive protein were 
determined. Moreover, lipoprotein metabolism was also 
explored through evaluation of the lipid profile and 
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the activity of cholesteryl ester transfer protein and 
lipoprotein associated phospholipase A2, which is also 
considered a specific marker of vascular inflammation. 
The protocol was approved by the Ethic Committee 
from School of Pharmacy and Biochemistry, University 
of Buenos Aires and from Buenos Aires Italian Hospital, 
Buenos Aires, Argentina.
RESULTS 
Regarding the indicators of insulin resistance, CD 
patients showed higher plasma insulin levels [7.2 
(5.0­11.3) mU/L vs  4.6 (2.6­6.7) mU/L, P  < 0.05], 
increased Homeostasis Model Assessment­Insulin 
Resistance [1.45 (1.04­2.24) vs  1.00 (0.51­1.45), P  < 
0.05] and lower Quantitative Sensitive Check index [0.33 
(0.28­0.40) vs  0.42 (0.34­0.65), P  < 0.05] indexes. 
Folic acid concentration [5.4 (4.4­7.9) ng/mL vs  12.2 
(8.0­14.2) ng/mL, P  < 0.01] resulted to be lower and 
High­sensitivity C reactive protein levels higher (4.21 
± 6.47 mg/L vs  0.98 ± 1.13 mg/L, P  < 0.01) in the 
patient group. With respect to the lipoprotein profile, 
CD patients showed lower high density lipoprotein­
cholesterol (HDL­C) (45 ± 15 mg/dL vs 57 ± 17 mg/dL, P  
< 0.05) and apo A­I (130 ± 31 mg/dL vs 155 ± 29 mg/
dL, P  < 0.05) levels, as well as higher total cholesterol/
HDL­C [4.19 (3.11­5.00) vs  3.52 (2.84­4.08), P  < 
0.05] and apo B/apo A­I (0.75 ± 0.25 vs  0.55 ± 0.16, 
P  < 0.05) ratios in comparison with control subjects. 
No statistically significant differences were detected 
in lipoprotein­associated lipid transfer protein and 
enzymes.
CONCLUSION
The presence and interaction of the detected alterations 
in patients with CD, would constitute a risk factor for the 
development of atherosclerotic cardiovascular disease.
Key words: Inflammation; Cardiovascular disease; High 
density lipoprotein-cholesterol; Lipoproteins; Celiac 
disease
© The Author(s) 2017. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: Given that data about the presence of meta­
bolic alterations and atherogenic risk factors in celiac 
disease are scarce and contradictory, we aimed to 
investigate carbohydrate metabolism, lipoprotein pro­
file and inflammatory status in patients with celiac 
disease (CD). Patients presented higher insulin levels, 
Homeostasis Model Assessment­Insulin Resistance 
index, apo B/apo A­I ratio and High­sensitivity C reactive 
protein concentration, as well as lower Quantitative 
Sensitive Check index index, high density lipoprotein­
cholesterol and apo A­I levels in comparison with sex 
and aged­matched healthy controls. Persistence of these 
alterations through long periods of time in a chronic 
pathologic condition, as it is the case with CD, would 
constitute a high risk of developing atherosclerotic 
cardiovascular disease.
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INTRODUCTION
Celiac disease (CD) is a multisystemic disease which 
mainly affects the digestive system, though not 
exclusively. Its main trait is chronic and diffuse inflam­
mation of the mucosa of the small intestine and it can 
present a wide variety of clinical symptoms[1]. Thus 
far, the only available therapy for CD consists of the 
implementation of a gluten free diet (GFD), whose effi­
cacy depends on strict adherence. 
It is remarkable that most cases of CD lack typical 
gastrointestinal symptoms and are, instead, very fre­
quently associated with presentations known as atypical 
or extra­intestinal. Thus, its diagnosis represents one of 
the main challenges for health professionals[2].
Commonly, CD has been associated with certain phy­
siopathological conditions (type 1 diabetes, Hashimoto 
thyroiditis, etc.) which are not directly related to glu­
ten ingestion[3]. Among these conditions, it is worth 
noting that the evidence linking CD and atherosclerotic 
cardiovascular disease (CVD) is scarce. It is well known 
that CD patients do not show classical CVD risk factors. 
In fact, hypertension and hypercholesterolemia are less 
frequent in CD patients than in the general population[4]. 
However, previous studies have failed to show lower 
CVD risk in CD patients than in healthy subjects[4,5]. 
Furthermore, an important study carried out in Sweden 
in approximately 14000 hospitalized CD patients 
showed higher risk of acute myocardial infarction, chest 
angina, cardiac insufficiency, brain hemorrhage and 
ischemic stroke when compared to sex and age­paired 
healthy controls[6].
These facts suggest that CD would be associated 
with novel atherogenic risk factors or even with other 
non­identified risk factors. In fact, inflammation and 
anemia, among other signs that characterize CD, could 
represent a link between this pathology and CVD[7,8].
Atherosclerosis is presently understood as a chronic 
inflammatory disease in which endothelial dysfunction 
and biomarkers of inflammation are present since the 
early stages of the pathology[9]. So far, the inflammatory 
process typical of CD has not been described in relation 
to increased risk of CVD.
The aim of the present study was to evaluate novel 
risk factors and biomarkers of CVD in CD patients in 
comparison to sex, age and body mass index (BMI)­
matched healthy controls. In addition, the metabolic 
differences between patients with typical and atypical 
presentations of the disease were also analyzed.
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MATERIALS AND METHODS
Subjects
Twenty patients with CD were consecutively recruited 
from the service of gastroenterology, Buenos Aires 
Italian Hospital, during a period of 12 mo. The inclusion 
criteria were adult age and recent diagnosis of CD (< 
3 mo) based on histopathological findings and sero­
logical markers (anti­gliadin IgG and IgA and anti­
transglutaminase IgA). Patients were not treated 
and they had not still started a GFD. All individuals 
presenting any other intestinal inflammatory disease, 
IgA deficiency, malignant diseases, chronic infections, 
pregnancy, thyroid, renal or hepatic alterations, history 
of CVD, smoking, alcohol consumption > 40 g/d, and 
treatment with drugs known to affect lipid and/or 
carbohydrate metabolism were excluded. Patients were 
classified according to the presence of gastrointestinal 
(typical presentation) or extra­digestive symptoms 
(atypical presentation)[2]. Gastrointestinal manifestations 
analyzed were: Diarrhea, abdominal distention, weight 
loss, and malabsorption syndrome. Extra­digestive 
alterations considered were: Anemia, mouth ulcers, 
osteoporosis, and modifications of liver function tests. 
Employing these criteria, 11 out of the 20 CD patients 
showed gastrointestinal symptomatology and 9 showed 
only extradigestive symptoms. The group of CD patients 
was compared with a sex, age and BMI­matched group 
of healthy volunteers (n = 20). Weight, height and waist 
circumference were registered in all subjects and an 
exhaustive anamnesis was performed. All participants 
in the study signed an informed consent. The protocol 
was approved by the Ethical Committees from School of 
Pharmacy and Biochemistry, University of Buenos Aires 
and from Buenos Aires Italian Hospital. Buenos Aires, 
Argentina.
Study protocol and samples
Blood samples were obtained from the antecubital vein 
after 12 h of fasting. Serum and EDTA plasma (final 
EDTA concentration 1 mg/mL) were prepared from 
venous blood collected into sterile, evacuated tubes. 
The former was centrifuged at 1500 g for 15 min at 
4 ℃. Serum was isolated and stored at 4 ℃ and ­70 ℃.
Determination of general biochemical parameters
Plasma concentrations of glucose, urea, uric acid, total 
bilirubin, folic acid and vitamin B12, as well as aspartate 
aminotransferase (ASAT), alanin aminotransferase and 
alkaline phosphatase activities, and hemogram were 
determined by standardized methods. Insulin levels 
were measured by radioimmunoassay (Diagnostics 
Products Corp., Los Angeles CA, United States). Homeos­
tasis Model Assessment­Insulin Resistance (HOMA­IR) 
was calculated using the formula [glucose (mmol/L) 
insulin (uU/mL)]/22.5 and Quantitative Sensitive 
Check index (QUICKI) using the formula 1/[ln Glucose 
(mmol/L) + ln Insulin (mU/L)][10,11]. High­sensitivity 
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C reactive protein (hsCRP) levels were determined by 
immunoturbidimetry (Roche, Mannheim, Germany) in a 
Hitachi 917 autoanalyzer (Tokyo, Japan).
Determination of the lipid, lipoprotein and apolipoprotein 
profile
Plasma levels of total cholesterol (TC) and triglycerides 
were quantified by standardized methods (Roche, 
Manheim, Germany) in a Hitachi 917 autoanalyzer 
(Tokyo, Japan). High density lipoproteins (HDL) were 
isolated from the supernatant obtained after selective 
precipitation of apolipoprotein (apo) B­containing 
lipoproteins using 0.44 mmol/L phosphotungstic acid 
in presence of magnesium ions[12]. Cholesterol (C) of 
low density lipoprotein (LDL) was estimated as the 
difference between TC and the cholesterol contained in 
the supernatant obtained after selective precipitation of 
LDL with 10 g/L polivinil sulfate in poliethileneglicol (600 
Da; 2.5 w/v; pH = 6.7)[13]. Non HDL­C was calculated as 
the difference between TC and HDL­C. Very low density 
lipoprotein cholesterol (VLDL­C) was calculated as the 
difference between the supernatants of the LDL­C and 
HDL­C precipitations. Apo B and apo A­I levels were 
quantified by immunoturbidimetry (Roche, Manheim, 
Germany) in a Hitachi 917 autoanalyzer (Tokyo, Japan). 
Results were expressed as mg/dL. The following ratios 
were calculated: TG/HDL­C, TC/HDL­C and apo B/apo 
A­I.
Determination of cholesteryl ester transfer protein 
activity
Cholesteryl ester transfer protein (CETP) activity was 
evaluated in serum samples following the radiometric 
method previously described with minor modifications[14]. 
Briefly, the capacity of the serum to promote the 
transfer of tritiated esterified cholesterol (EC) from the 
biosynthetically marked HDL3 subfraction (3H­EC­HDL3) 
(NEN Life science products, Boston, United States) to 
apo B containing lipoproteins present in the serum. 
Serum samples were incubated with 3H­CE­HDL3 (50 
µmol/L cholesterol) with iodoacetate (1.5 mmol/L) 
in TBS buffer (pH = 7.4) during 3 h at 37 ℃. After 
incubation, apo B­containing lipoproteins were separated 
from HDL by selective precipitation with phosphotungstic 
acid (0.44 mmol/L) in the presence of magnesium ions. 
Radioactivity was measured in the reaction cocktail and 
in the supernatant containing the HDL subfraction in 
a liquid scintillation counter (Packard 210 TR, Packard 
Instruments, Meridians, CT, United States). Results were 
expressed as the percentage of tritiated EC transferred 
from HDL3 to apo B­containing lipoproteins, per ml, per 
hour. All samples were processed in the same assay.
Determination of lipoprotein associated phospholipase 
A2 activity
Lipoprotein associated phospholipase A2 activity (Lp­
PLA2) was evaluated employing the radiometric assay 
described by Blank et al[15] with minor modifications. 
Tetzlaff WF et al . CVD risk in celiac disease
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RESULTS
As expected, CD patients and control subjects did 
not show any difference in age, sex distribution and 
BMI (Table 1). Nevertheless, CD patients had signifi­
cantly higher insulin levels and HOMA­IR, as well as 
lower QUICKI (Table 1). Both urea and creatinine 
concentrations were lower in the patient group, though 
individual results were comprised within the reference 
values. Additionally, ASAT activity was significantly 
increased in patients compared to controls.
The evaluation of hematological parameters showed 
no significant decrease in hemoglobin concentration 
in patients. Furthermore, only one woman met the cri­
teria for anemia diagnosis (hemoglobin < 12 g/dL for 
women and < 13 g/dL for men). Similarly, there were 
no differences in total iron content, transferrin satura­
tion or concentrations of ferritin, transferrin and vita­
min B12. Only folic acid concentration was found to 
be significantly lower in patients (Table 2). Employing 
the reference values established by the World Health 
Organization[16,17], the prevalence of folic acid deficiency 
resulted to be 10% (< 4 ng/dL), of iron deficiency 15% 
(ferritin < 15 ng/dL) and of low vitamin B12 7.5% (< 
203 pg/mL).
Regarding the lipid and lipoprotein profile, no differ­
ences were detected in TG, TC, LDL­C and apo B levels. 
However, statistically significant decreases in HDL­C 
and apo A­I concentrations were observed (Table 3). 
Furthermore, both parameters showed a strong positive 
correlation between them (r = 0.78; P < 0.0001). TC/
HDL­C and apo B/apo A­I ratios, both of which possess 
high predictive value for CVD, were significantly higher in 
patients, whilst TG/HDL­C showed no difference between 
groups. On the other hand, CETP activity was similar in 
patients and controls (145% ± 32%/mL.h vs 132% ± 
33%/mL.h, P > 0.05) and exhibited direct correlations 
with TG levels (r = 0.52; P < 0.005) and apo B/apo 
A­I ratio (r = 0.48; P < 0.005), and negative ones with 
HDL­C (r = ­0.58; P < 0.0001) and apo A­I (r = ­0.40; P 
< 0.005).
The extraction of the marked acetate was performed 
using chloroform and the radioactivity of the aqueous 
phase was measured in a liquid scintillation counter 
(Packard 210 TR, Packard Instruments, Meridians, CT, 
United States). The radioactivity of the reaction buffer 
was also measured. Results were expressed as µmol 
of acetate liberated, per millilitre, per hour. All samples 
were processed in the same assay.
Statistical analysis
The sample size was calculated based on previous 
studies carried out in our laboratory. The outcome 
variables chosen to perform the sample size calculation 
for this study were HDL­C, CETP and Lp­PLA2. Having 
defined a 0.8 power, an effect size of 1.0 and a signifi­
cance level of 0.05, the number of patients to be 
included in the present study was at least 17. Data 
distribution was analyzed with the Shapiro­Wilks test 
and data was expressed as mean ± SD, if distribution 
was found to be parametric, or as median (interquartile 
range) if distribution was non­parametric. To assess 
differences between groups, both parametric and 
non­parametric methods were employed. Correlation 
analyses were performed using Spearman or Pearson 
tests depending on variable distribution. When partial 
correlations, linear regressions or adjusted group 
differences were performed, all non­parametric variables 
were normalized prior to be included in the analysis. 
Statistical significance was defined as P < 0.05. A 
statistical review of the study was performed by a 
biomedical statistician. For the statistical analysis, the 
programs Infostat (Universidad Nacional de Cordoba, 
Argentina) and SPSS 19.0 (IBM, Chicago, United States) 
were used.
Patients with celiac 
disease
(n  = 20)
Control 
subjects
(n = 20)
P
  Age (yr) 50 (25-58) 47 (28-60) ns
  Men/woman 5/15 5/15 ns
  BMI (kg/m2) 22.8 (20.4-26.2) 23.0 (21.0-24.7) ns
  Glucose (mg/dL) 87 ± 11 86 ± 12 ns
  Insulin (mU/L) 7.2 (5.0-11.3) 4.6 (2.6-6.7) < 0.05
  HOMA-IR 1.45 (1.04-2.24) 1.00 (0.51-1.45) < 0.05
  QUICKI 0.33 (0.28-0.40) 0.42 (0.34-0.65) < 0.05
  Urea (mg/dL) 27 (21-34) 35 (34-39) < 0.01
  Creatinine (mg/dL) 0.74 (0.63-0.88) 0.80 (0.75-1.10) < 0.05
  Uric acid (mg/dL) 5.0 ± 1.2 4.3 ± 1.6 ns
  Bilirubin (mg/dL) 0.7 (0.5-0.8) 0.6 (0.6-0.8) ns
  ASAT (U/L) 26 (20-35) 14 (12-20) < 0.01
  ALAT (U/L) 22 (17-39) 18 (16-22) ns
  ALP (U/L) 80 (59-102) 124 (67-219) ns
Table 1  Clinical and biochemical characteristics from patients 
with celiac disease and control subjects
BMI: Body mass index; HOMA-IR: Homeostasis Model Assessment 
insulin resistance; QUICKI: Quantitative insulin sensitivity check index; 
ASAT: Aspartate-amine transferase; ALAT: Alanine-amine transferase; 
ALP: Alkaline phosphatase; ns: Non significant. Data are shown as mean ± 
SD or median (interquartile range) according to data distribution. 
Patients with 
celiac disease
(n  = 20)
Control 
subjects
(n  = 20)
P
  Erythrocytes (106/mL) 4.40 ± 0.48 4.58 ± 0.27 ns
  Hematocrite (%) 38.5 ± 4.0 40.1 ± 2.6 ns
  Hemoglobin (g/dL) 13.0 ± 1.4 13.3 ± 0.9 ns
  Serum iron (µg/dL) 73 ± 35 105 ± 61 ns
  Ferritin (ng/mL) 33 (13-110) 92 (43-117) ns
  Transferrin (mg/dL) 261 ± 62 293 ± 59 ns
  Transferrin Sat. (%) 25 ± 14 29 ± 14 ns
  Vitamin B12 (pg/mL) 337 (251-482) 315 (265-393) ns
  Folic acid (ng/mL) 5.4 (4.4-7.9) 12.2 (8.0-14.2) < 0.01
Table 2  Hematological parameters from patients with celiac 
disease and control subjects
ns: Non significant; Sat.: Saturation. Data are shown as mean ± SD or 
median (interquartile range) according to data distribution.
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show higher CVD morbidity and mortality[18,19], avai­
lable evidence for CD appears less solid and more con­
troversial. Even though some studies have described 
an increase in CVD risk compared with the general 
population[20­22], this has not been the case in other 
reports[4,23]. A group of CD patients, retrospectively 
studied in comparison with data from general popula­
tion[24], showed less CVD risk employing the Framing­
ham score. Nevertheless, assessment of cardiac fun­
ctionality, specifically of the left ventricle[25], and the 
study of the presence of subclinical atherosclerosis, 
analyzed through aortic stiffness, aortic strain, and aortic 
distensibility[26,27], evidenced a clear association between 
CD and CVD. Moreover, a previous study showed higher 
carotid intima media thickness (an established marker 
of generalized atherosclerosis that correlates with the 
extent of coronary artery disease and predicts future 
cardiovascular events) in CD patients compared to 
healthy controls and similar to that of patients with type 
1 diabetes[28]. Lastly, it is worth noting that a recent 
meta­analysis[29], based on ten studies performed in CD 
patients, showed a slight increase in the risk of stroke, 
acute myocardial infarction, and cardiovascular death, 
though only in the first case this increase reached statisti­
cal significance. As evidenced by the bibliography, the 
subject remains highly controversial. 
In CD patients, a systemic pro­inflammatory status 
was evidenced through an increase in plasma hsCRP 
levels. According to the guides of the American Heart 
Association[30], values above 3 mg/dL, such as those 
observed in the group of the CD patients studied, 
would be indicative of high CVD risk. Even though Lp­
PLA2 activity, considered a specific marker of vascular 
inflammation[31], showed no differences between 
patients and controls, there is solid evidence about the 
increase of other inflammation markers in CD. In this 
regard, a previous study reported an increase in tumor 
necrosis factor (TNF)­α­producing innate lymphoid cells 
in the intestinal mucosa of untreated CD patients in 
comparison with treated patients and healthy controls[32]. 
Evaluation of inflammation markers showed an 
increase in hsCRP levels in CD patients (Figure 1), 
which also correlated with apo B/apo A­I ratio (r = 0.42; 
P < 0.01). Even though white blood cell count (WBC) 
showed no differences between the two groups (6.11 
± 1.31 103/mL vs 6.17 ± 1.15 103/mL), it was directly 
associated with several parameters of the lipid profile (r/
p; TG, 0.33/< 0.05; HDL­C, ­0.34/< 0.05; apo B, 0.42/< 
0.05; TG/HDL­C, 0.37/< 0.05; TC/HDL­C, 0.44/< 0.01; 
and apo B/apo A­I, 0.51; < 0.005). Lastly, Lp­PLA2 
activity was similar between patients and controls (7.20 
± 1.28 µmol/mL.h vs 7.91 ± 2.02 µmol/mL.h) and was 
positively associated with LDL­C, main carrier of the 
enzyme in circulation (r = 0.50; P < 0.005).
Moreover, folic acid level was significantly associated 
with several parameters of the lipid profile (r/p; HDL­C, 
0.52/< 0.05; apo A­I, 0.45/< 0.01; TG/HDL­C, ­0.36/< 
0.05; and apo B/apo A­I, ­0.34/< 0.05) and with hsCRP 
concentration (r = ­0.42; P < 0.05).
When comparing patients according to the clinical 
features, no differences were detected between patients 
with typical and atypical presentation of the disease in 
any of the parameters analyzed (data not shown). 
DISCUSSION
Patients with CD showed a slight alteration in carbohy­
drate metabolism, decreased folic acid levels, a more 
atherogenic lipoprotein profile and an increase in 
the inflammatory marker hsCRP, with no difference 
evidenced between typical and atypical presentation 
of the disease. Likely, in both groups, the severity of 
duodenal lession would not be a determining factor in 
the metabolic alterations nor in the increase of hsCRP 
observed in this study.
Unlike other pathologies characterized by the 
presence of systemic inflammation, such as lupus ery­
thematosus and rheumatoid arthritis, in which patients 
Patients with 
celiac disease
(n  = 20)
Control 
subjects
(n  = 20)
P
  TG (mg/dL) 81 (65-119) 78 (60-114) ns
  TC (mg/dL) 185 ± 37 194 ± 39 ns
  VLDL-C (mg/dL) 18 ± 8 17 ± 7 ns
  LDL-C (mg/dL) 139 (89-149) 107 (95-147) ns
  HDL-C (mg/dL) 45 ±15 57 ±17 < 0.05
  Non-HDL-C (mg/dL) 153 (105-167) 137 (112-167) ns
  Apo A-I (mg/dL) 130 ± 31 155 ± 29 < 0.05
  Apo B (mg/dL) 93.6 ± 23.8 83.5 ± 20.7 ns
  TG/HDL-C 2.09 (1.13-2.98) 1.29 (1.06-1.93) ns
  TC/HDL-C 4.19 (3.11-5.00) 3.52 (2.84-4.08) < 0.05
  ApoB/apo A-I 0.75 ± 0.25 0.55 ± 0.16 < 0.01
Table 3  Lipid, lipoprotein and apolipoprotein profile from 
patients with celiac disease and control subjects
TG: Triglycerides; TC: Total cholesterol; VLDL: Very low density 
lipoprotein; LDL: Low density lipoprotein; HDL: High density lipoprotein; 
apo: Apolipoprotein; ns: Non significant. Data are shown as mean ± SD or 
median (interquartile range) according to data distribution.
CD patients          Controls subjects
hs
­C
R
P 
(m
g/
L)
6
5
3
2
0
Figure 1  Levels of high sensitive C-reactive protein in patients with celiac 
disease (n = 20) and control subjects (n = 20). bP < 0.01. hsCRP: High 
sensitive C reactive protein; CD: Celiac disease.
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this alteration could result from a lower synthesis and 
secretion of apo A­I[56]. Furthermore, longitudinal studies 
described an increase in HDL­C and apo A­I values 
after initiation of treatment with GFD[51]. In addition, CD 
patients presented an increase in TC/HDL­C and apo 
B/apo A­I ratios[57], which reflect an imbalance between 
proatherogenic and antiatherogenic lipid factors. Another 
possibility that could explain HDL­C decrease is that HDL 
particles from CD patients would possess less capability 
to promote cholesterol efflux from cells. In fact, apo A­I 
has not only got a structural role in HDL particles, but 
it is also involved in multiple antiatherogenic functions 
including cholesterol efflux promotion[58]. Due to the 
decrease in intestinal apo A­I synthesis, the number 
of circulating HDL particles would be diminished 
and, in turn, each particle would be depleted in this 
apolipoprotein. As a matter of fact, in other inflammatory 
pathologies such as rheumatoid arthritis, alterations in 
HDL functionality have been associated with higher risk 
of CVD[59]. Study of HDL functions in affected patients 
could provide important evidence linking CD and CVD 
risk. 
Regarding hematological parameters, only folic acid 
was decreased in CD patients. This finding is consistent 
with previous reports that show a decrease in folic 
acid levels as a consequence of impaired intestinal 
absorption, resulting from the damage to the intestinal 
epithelium caused by the inflammatory process[60]. 
This folic acid deficiency persists, in many cases, even 
after the initiation of treatment with GFD[61]. It is worth 
noting that a decrease in folic acid levels may lead to 
an increase in homocysteine concentration. One of 
the main homocysteine clearance pathways consists 
of its re­methylation and recycling to methionine, a 
process catalyzed by the methionine synthase (MTR) 
enzyme, which links the folate cycle with homocysteine 
metabolism[62]. In fact, different studies showed higher 
homocysteine levels in CD patients[26,63,64]. Importantly, 
this increment was independently associated with 
increased risk and severity of coronary artery disease[65]. 
Moreover, high homocysteine levels were also identified 
as independent predictors of a suboptimal response 
to antiplatelet therapy with acetyl salicylic acid, thus 
favouring thrombotic complications in patients with 
coronary artery disease[66]. In addition, in a meta­
analysis of randomized controlled trials, Liu et al[67] 
demonstrated that folic acid supplementation could 
improve the endothelial dysfunction observed in patients 
with coronary artery disease. Nevertheless, studies on 
homocysteine­lowering interventions with vitamin B6, 
folic acid (vitamin B9) or vitamin B12, administrated 
alone or in combination with the purpose of preventing 
cardiovascular events, failed to consistently demonstrate 
their efficacy[68]. Therefore, consideration of increased 
homocysteine levels as a risk factor for CVD is still a 
controversial topic[69]. 
In the present study, newly diagnosed CD patients, 
who were not following a GFD, presented higher insulin 
Moreover, an increase in TNF­α and interleukin (IL)­6 
levels has been reported in the epithelium and the 
lamina propia of the intestinal mucosa of untreated CD 
patients[33,34]. Additionally, higher levels of IL­6 have 
been observed in the plasma of untreated CD patients 
compared to treated ones and healthy controls[35,36]. 
Regarding markers of carbohydrate metabolism, 
even though insulin levels and HOMA­IR were increased 
and QUICKI diminished, the analysis of the individual 
values did not allow the diagnosis of insulin resistance 
in any of the patients included in the present study. 
In fact, the results obtained were below the values 
reported for patients with metabolic syndrome or type 
2 diabetes, though above those reported for the general 
population[37­40]. Nevertheless, even the presence 
of a subtle alteration in carbohydrate metabolism in 
untreated CD patients would possess great clinical 
impact. Actually, GFD, the only available treatment for 
CD, contains higher caloric density than similar diets 
based on gluten containing foods, and its implementa­
tion could, as a result, increase the risk of developing 
obesity, and, consequently, metabolic syndrome and 
diabetes[41­43]. Therefore, assessment of fasting glucose 
and insulin in patients diagnosed with CD before and 
during the introduction of GFD should be performed. 
However, the subject is still controversial. Kabbani et 
al[44] reported lower prevalence of metabolic syndrome 
and type 2 diabetes in patients under GFD treatment, 
regardless of treatment duration. Moreover, experiments 
carried out in C57BL/6 mice fed on a hyper fat diet with 
and without gluten showed that GFD reduced insulin 
resistance, adiposity and inflammation[45], although it is 
necessary to consider that these mice did not present 
CD. In the present study, the finding of significantly 
higher insulin levels and HOMA­IR and lower QUICKI 
than in controls suggests the presence of a slightly 
altered carbohydrate metabolism, which could be related 
to the pro­inflammatory status described in CD patients 
and evidenced in our study by higher hsCRP levels. It 
has been previously proposed that inflammation could 
be a causative agent for alterations in carbohydrate 
metabolism through the action of cytokines such as 
TNF­α, IL­6 and IL­1β, among others[46,47].
Studying lipoprotein profile in CD patients appears 
interesting, since there is evidence for both a decrease 
in cholesterol absorption and an increase in its synthe­
sis[48­50]. In the current study, patients showed TC and 
LDL­C levels similar to controls. These findings are in 
disagreement with the decrease in both parameters 
previously reported for CD patients[5,51,52]. Patients evalu­
ated in this study also presented lower HDL­C levels. 
There is prior evidence showing a 12% prevalence of CD 
in patients with low HDL­C concentration[53], much higher 
than that reported for the general population, which 
implies a causal relationship between the presence of CD 
and the decrease in HDL­C. Unlike in the case of patients 
with insulin resistance[54,55], this decrease was not found 
to be associated with higher CETP activity. Therefore, 
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This is an interesting study showing that patients with CD do have an ather­
ogenic lipoprotein profile that may dispose them to develop CVD.
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